You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 264 No. 8, August 22, 1990 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communication
 This Article
 •References
 •Full text PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (23)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Bovine Somatotropin Supplementation of Dairy Cows

Is the Milk Safe?

William H. Daughaday, MD; David M. Barbano, PhD

JAMA. 1990;264(8):1003-1005.


Abstract

Complex, biologically active proteins (eg, enzymes and hormones) can be manufactured safely and cost-effectively through applications of biotechnology. Some of these proteins (eg, human insulin, human somatotropin, rennet for cheese manufacture) are currently approved for medical or food processing applications. Bovine somatotropin (bST) for lactating dairy cattle is another product that can be produced via biotechnology and may allow dairy farmers to produce milk at a lower cost. In 1985, based on an evaluation of toxicological data, the Food and Drug Administration concluded that milk and meat from bST-supplemented cows was safe and wholesome. The Food and Drug Administration has authorized the use of milk and meat from bST-supplemented cows in the commercial food supply. Its evaluation of the impact of bST supplementation on the long-term health of dairy cattle is near completion, and bST may be approved for commercial use in early 1991.

(JAMA. 1990;264:1003-1005)



Author Affiliations

From the Department of Internal Medicine, Metabolism Division, Washington University School of Medicine, St Louis, Mo (Dr Daughaday), and the Department of Food Science, Cornell University, Ithaca, NY (Dr Barbano).; From 1984 to 1986, Dr Daughaday was the recipient of a research contract from Monsanto Company, a small fraction of which was paid to Dr Daughaday as a consulting fee. The contract was for purification of bovine insulinlike growth factor I from blood. Dr Daughaday has not received any funds from Monsanto subsequent to the above agreement.; Dr Barbano acted on behalf of Cornell University as the principal investigator for a research contract between Cornell University and Monsanto Agricultural Company entitled "Chemical Composition and Dairy Product Processing Characteristics of Milk Produced by Cows Treated With Recombinant Somatotropin" from January 1, 1986, through December 31, 1988.


Footnotes

Reprint requests to Cornell University Institute of Food Science, Stocking Hall, Ithaca, NY 14853-7201 (Dr Barbano).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dairy Product Consumption and the Risk of Breast Cancer
Parodi
J. Am. Coll. Nutr. 2005;24:556S-568S.
ABSTRACT | FULL TEXT  

Biology of Somatotropin in Growth and Lactation of Domestic Animals
ETHERTON and BAUMAN
Physiol. Rev. 1998;78:745-761.
ABSTRACT | FULL TEXT  

Bovine Somatotropin
Kronfeld
JAMA 1991;265:1389-1389.
ABSTRACT  

Bovine Somatotropin
Epstein
JAMA 1991;265:1391-1391.
ABSTRACT  

Genetic Engineering and the Use of Bovine Somatotropin
Grossman
JAMA 1990;264:1028-1028.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.